Principal Investigator
Jay Spiegel
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20250408
Clinical Trial Summary
Immunoglobulin Replacement Therapy and Infectious Complications After CD19-Targeted CAR-T-Cell Therapy
Phase
Phase II
Funding Agency/Sponsor
National Cooperative Group
Disease
Transplant/cellular therapy
Contact Information
Phone Number
305-243-2647